Keyphrases
Experimental Pulmonary Hypertension
100%
Fibroblast Phenotype
100%
Fluvastatin
100%
Adventitial Fibroblasts
100%
Statins
60%
P38 Mitogen-activated Protein Kinase (p38 MAPK)
60%
Hypoxic Pulmonary Hypertension
60%
Fibroblast Proliferation
60%
Pulmonary Artery
40%
Rac1
40%
Phenotypic Change
40%
Mitogen
40%
Public Health Risk
20%
Fibroblasts
20%
Conditioned Medium
20%
Mechanism of Action
20%
Lung Disease
20%
Pulmonary Artery Smooth muscle Cells (PASMCs)
20%
Bovine Cells
20%
Pulmonary Artery Smooth muscle Cell Proliferation
20%
Chronic Hypoxia
20%
Pulmonary Vascular Remodeling
20%
Signaling Pathway
20%
Co-culture Model
20%
P38 Mitogen-activated Protein Kinase Inhibitor
20%
High-altitude Resident
20%
Kinase Phosphorylation
20%
Treprostinil
20%
Cholesterol Pathway
20%
Sildenafil
20%
Bosentan
20%
Phenotypic Switching
20%
Pharmacology, Toxicology and Pharmaceutical Science
Experimental Pulmonary Hypertension
100%
Fluindostatin
100%
Pulmonary Hypertension
60%
Mitogen Activated Protein Kinase P38
60%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
40%
Mitogenic Agent
40%
Hypoxia
20%
Vascular Remodeling
20%
Lung Disease
20%
Mitogen Activated Protein Kinase P38 Inhibitor
20%
Sildenafil
20%
Bosentan
20%
Treprostinil
20%
Statin (Protein)
20%
Diseases
20%